GenesisCare joins international MOMENTUM data registry to propel innovation with MRI-guided radiation therapy
Sydney, Australia, Monday 28th April 2025 - GenesisCare’s world-leading approachiii to MRI-guided radiation therapy has been strengthened as it joins the international data sharing network known as MOMENTUM.
MRI-guided radiation therapy was introduced to Australia about five years ago and uses technology that monitors tumour movements in real time so that radiation can be more precisely targeted to the cancerous cells and avoid healthy tissue and organs, which can result in fewer side effects and treatment sessions for patientsiiiiv. Since its introduction at two GenesisCare centres in 2020 and then later in 2022, just over 1000 patients have been treated with the technology.
The MOMENTUM data registry, part of the MR-Linac Consortium, collects de-identified information from more than 80 cancer care centres around the world using the MR-Linac to treat patients with MRI-guided radiation therapy. The registry collects tumour staging information and technical data such as treatment imaging. Membership of the data registry offers clinical teams worldwide a chance to participate in future clinical research, benchmark their treatments against an international standard and identify practices that may help improve patient outcomes and the efficiency of treatment.
GenesisCare operates two of Australia’s four MR-Linac machines in Sydney and Perth. Since introducing the treatment, GenesisCare researchers have since become global pioneers in new ways of using the MR-Linac, such as delivering Stereotactic Ablative Radiation Therapy with a “sim-less” workflow, which shortens a prostate cancer patient’s wait time for treatment.
GenesisCare Radiation Oncologist Dr Jeremy de Leon and leader of the MR-Linac research program in Sydney said: “Joining the MOMENTUM registry will be pivotal for our ongoing MR-Linac research program at GenesisCare. With access to global data in this registry we hope to validate our research methods and results so we can demonstrate the potential of MRI-guided radiation therapy with hard data.”
GenesisCare Radiation Oncologist Dr Hendrick Tan of the MR-Linac research program in Perth said: “The aim of our MR-Linac research is to maximise precision radiation therapy approaches to hopefully improve patient outcomes, tumour control and quality of life. Joining this international network of data and like-minded researchers strengthens our resolve to reach our goals as we work towards better results for cancer patients.”
The MR-Linac is a promising treatment option for tumours that are located near other major organs where limiting damage to healthy tissue is important or in organs that tend to move a lot such as the upper abdomen due to breathingv. This technology may be a potential treatment option for a range of cancer types including liver, pancreatic, rectal, bladder, kidney and prostate cancervi. It is also beneficial in the treatment of metastases, where cancer has spread to other parts of the body.
For more information on GenesisCare centres involved in this research, please visit our website here:
GenesisCare in Darlinghurst, Sydney:
https://www.genesiscare.com/au/our-centres/st-vincents-sydney
GenesisCare in Murdoch, Perth:
https://www.genesiscare.com/au/our-centres/fiona-stanley-hospital
Media contact information
Contact our media team directly for futher information:
i‘Adapting outside the box: Simulation-free MR-guided stereotactic ablative radiotherapy for prostate cancer’, Radiotherapy and Oncology, Volume 200, November 2024: https://www.sciencedirect.com/science/article/pii/S0167814024035059
ii’Towards simulation-free MR-Linac treatment: utilizing male pelvis PSMA-PET/CT and population-based electron density assignments,’ Physics in Medicine and Biology, published 22 September 2023: https://iopscience.iop.org/article/10.1088/1361-6560/acf5c6/meta
iii Castelluccia A, et al. Int J Environ Res Public Health 2022;19:10800.
iv Hall WA, et al..CA Cancer J Clin 2022;72:34–56.
v Hall WA, et al..CA Cancer J Clin 2022;72:34–56.
vi Radiat Oncol. 2023;18(1):2221-8. doi:10.1186/s13014-023-02221-8.
The aim of our MR-Linac research is to maximise precision radiation therapy approaches to hopefully improve patient outcomes, tumour control and quality of life.
- Dr Hendrick Tan, GenesisCare Radiation Oncologist, MR-Linac research program, Perth
